239 related articles for article (PubMed ID: 18688028)
21. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.
Nash MA; Loercher AE; Freedman RS
Cancer Res; 1999 Dec; 59(24):6192-6. PubMed ID: 10626812
[TBL] [Abstract][Full Text] [Related]
22. Adaptation of sensory neurons to hyalectin and decorin proteoglycans.
Lemons ML; Barua S; Abanto ML; Halfter W; Condic ML
J Neurosci; 2005 May; 25(20):4964-73. PubMed ID: 15901777
[TBL] [Abstract][Full Text] [Related]
23. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
24. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
[TBL] [Abstract][Full Text] [Related]
25. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
27. Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.
Mondal DK; Xie C; Pascal GJ; Buraschi S; Iozzo RV
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317760121. PubMed ID: 38652741
[TBL] [Abstract][Full Text] [Related]
28. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth.
Ständer M; Naumann U; Wick W; Weller M
Cell Tissue Res; 1999 May; 296(2):221-7. PubMed ID: 10382266
[TBL] [Abstract][Full Text] [Related]
30. Effects of rhDecorin on TGF-beta1 induced human hepatic stellate cells LX-2 activation.
Shi YF; Zhang Q; Cheung PY; Shi L; Fong CC; Zhang Y; Tzang CH; Chan BP; Fong WF; Chun J; Kung HF; Yang M
Biochim Biophys Acta; 2006 Nov; 1760(11):1587-95. PubMed ID: 17067743
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
32. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
33. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
[TBL] [Abstract][Full Text] [Related]
34. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis.
Sulochana KN; Fan H; Jois S; Subramanian V; Sun F; Kini RM; Ge R
J Biol Chem; 2005 Jul; 280(30):27935-48. PubMed ID: 15923192
[TBL] [Abstract][Full Text] [Related]
35. Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells.
Patel S; Santra M; McQuillan DJ; Iozzo RV; Thomas AP
J Biol Chem; 1998 Feb; 273(6):3121-4. PubMed ID: 9452417
[TBL] [Abstract][Full Text] [Related]
36. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
37. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
38. Retroviral overexpression of decorin differentially affects the response of arterial smooth muscle cells to growth factors.
Fischer JW; Kinsella MG; Levkau B; Clowes AW; Wight TN
Arterioscler Thromb Vasc Biol; 2001 May; 21(5):777-84. PubMed ID: 11348874
[TBL] [Abstract][Full Text] [Related]
39. Decorin promotes plasminogen/plasmin expression within acute spinal cord injuries and by adult microglia in vitro.
Davies JE; Tang X; Bournat JC; Davies SJ
J Neurotrauma; 2006; 23(3-4):397-408. PubMed ID: 16629625
[TBL] [Abstract][Full Text] [Related]
40. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
